Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp Sells 11,250 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $278.76 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a 50 day moving average price of $247.13 and a two-hundred day moving average price of $260.26. The firm has a market cap of $35.95 billion, a PE ratio of -106.40 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The firm’s revenue was down 33.3% compared to the same quarter last year. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research analyst reports. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Sanford C. Bernstein dropped their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, TD Cowen upped their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $298.61.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC boosted its holdings in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.